Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Frequently asked questions
What sector does TERNS PHARMACEUT.DL-0001 (430) operate in?
TERNS PHARMACEUT.DL-0001 belongs to the Other sector and operates in the industry.
What is TERNS PHARMACEUT.DL-0001 (430) current stock price?
As of the latest data, TERNS PHARMACEUT.DL-0001 stock price is €45.07, with a previous close of €45.07.
What is TERNS PHARMACEUT.DL-0001 (430) current market capitalization?
TERNS PHARMACEUT.DL-0001 market cap is approximately 5.21 billion.
What is TERNS PHARMACEUT.DL-0001 (430) Earnings Per Share (EPS)?
The trailing EPS is -€0.88.
Does TERNS PHARMACEUT.DL-0001 (430) pay dividends?
No. TERNS PHARMACEUT.DL-0001 does not pay a dividend.
What is TERNS PHARMACEUT.DL-0001 (430) beta (volatility) score?
TERNS PHARMACEUT.DL-0001 has a beta of -0.380, indicating lower volatility than the overall market.
